Home Research progress on N6-adenosylate methylation RNA modification in heart failure remodeling
Article Open Access

Research progress on N6-adenosylate methylation RNA modification in heart failure remodeling

  • Yiqing Yang , Mbikyo B Muisha , Junzhe Zhang , Yingxian Sun and Zhao Li EMAIL logo
Published/Copyright: January 5, 2023
Download Article (PDF)
Journal of Translational Internal Medicine
From the journal Journal of Translational Internal Medicine Volume 10 Issue 4

Abstract

Cardiovascular disease (CVD) is the major cause of disability-adjusted life years (DALY) and death globally. The most common internal modification of mRNA is N6-adenosylate methylation (m6A). Recently, a growing number of studies have been devoted to researching cardiac remodeling mechanisms, especially m6A RNA methylation, revealing a connection between m6A and cardiovascular diseases. This review summarized the current understanding regarding m6A and elucidated the dynamic modifications of writers, erasers, and readers. Furthermore, we highlighted m6A RNA methylation related to cardiac remodeling and summarized its potential mechanisms. Finally, we discussed the potential of m6A RNA methylation in the treatment of cardiac remodeling.

Key words: RNA modification; m6A RNA methylation; cardiac remodeling; cardiac hypertrophy; heart failure

Introduction

Cardiovascular diseases result from complicated interactions between multiple genetic variations and environmental factors.[1] Common fatal cardiovascular diseases include ischemic heart disease (IHD),[2,3] hypertensive heart disease,[4] cardiomyopathies,[5] and heart failure (HF),[6,7] among others. One of the global health policy goals launched by World Health Organization is to reduce early mortality from noncommunicable diseases by 25% by 2025.[8] Therefore, it is of great significance to study the mechanisms of cardiovascular disease.

Cardiac hypertrophy is an important factor in the pathogenesis of cardiovascular diseases. Physiological cardiac hypertrophy is typically caused by exercise or pregnancy.[9] It is characterized by a slight increase in cardiac mass (10%–20%) and an increase in the length and width of individual cardiomyocytes.[10] However, the heart shape is normal, and this process is advantageous to the cardiac function. Pathological cardiac hypertrophy includes altered cardiac gene expression, cell death, fibrosis, imbalance in Ca2+ transport regulatory proteins, mitochondrial dysfunction, changes in sarcomere structure, and inadequate angiogenesis.[11] The signaling mechanisms that induce these responses contribute to maladaptive heart remodeling and dysfunction, ultimately leading to heart failure. Inhibiting concurrent signaling pathways may also have important therapeutic significance.[9]

RNAs can be modified after transcription, and more than 170 types of RNA posttranscriptional modifications have been discovered to date.[12] An increasing number of inner modifications of eukaryotic epigenetics have been explored in recent studies, including well-known markers named histone tails.[13,14] RNA modifications involve adenosine N6-methyladenosine (m6A), N1- methyladenosine (m1A), 5-methylcytosine (m5C), pseudothiopyrimidine (Ψ), N6, 2’-O-dimethyladenosine (m6Am),[15] the methylation of cytosine to 5-methylcytosine and its oxidation product 5-hydroxymethylcytosine (hm5C),[13] N7-methylguanosine (m7G),[16] N4-acetylcytidine (ac4C),[17] and ribose methylations (Nm).[18] The most extensive modification of mammalian mRNA, N6-methyladenosine (m6A), has aroused widespread interest and scrutiny in the field.[19] Scientists have isolated RNA from mammals and discovered that approximately 1‰–4‰ of adenosine was modified as m6A, which made up about half of the total ribonucleotide methylation.[20] m6A is also found in precursor RNAs (pre-RNAs) and long noncoding RNAs (lncRNAs).[21] Generally, m6A is embedded in the conserved sequence 5’-RRACU-3’,[22] and it mainly occurs in the beginning segment of the 3’-UTR, which is near the translation end codon.[23] Currently, extensive studies are being conducted to investigate the connection between m6A and various diseases.[24, 25, 26] One of the research hotspots is tumorigenesis, but research reports on the relationship between m6A modification and cardiovascular diseases are still limited.[27] This review summarizes m6A RNA methylation and the regulation of RNA stability in cardiac remodeling. It also focuses on how research advances in the relationship between m6A modification and cardiac remodeling provide new ideas for the prevention, early detection, and treatment of cardiac hypertrophy and heart failure.

m6A RNA methylation

RNA modified as m6A refers to the methylation of N6 in the nitrogenous base adenine.[28] There are three key enzymes mediating this process: methyltransferases (writers), demethylases (erasers), and methylation-reading proteins (readers).[29] We summarized their participation in biological dynamic modification and function, as shown in Figure 1.

Figure 1 The dynamic modification of m6A. Writers (METTL3, METTL14, WTAP, METTL16, KIAA1429, RBM15/15B, ZFP127, ZC3H13, and ZCCHC4) can identify and methylate the N6 of RNA. Erasers (FTO, ALKBH5, ALKBH3) can catalyze m6A-RNA demethylation. m6A-RNA can be discerned by readers such as YTHDC1 for mRNA splicing. Other readers of m6A are located in the cytoplasm; for instance, YTHDF1, YTHDF2, YTHDF3, YTHDC2, HNRNPA2B1, HNRNPC/G, and IGF2BP1/2/3 are involved in the splicing, processing, translation, and degradation of m6A RNAs. METTL3: methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit; METTL14: methyltransferase 14, N6-adenosine-methyltransferase subunit; METTL16: methyltransferase 16, N6-methyladenosine; WTAP: WT1-associated protein; KIAA1429/VIRMA: vir-like m6A methyltransferase-associated; RBM15/15B: RNA-binding motif protein 15/15B; ZFP127/MKRN3: makorin ring finger protein 3; ZC3H13: zinc finger CCCH-type containing 13; ZCCHC4: zinc finger CCHC-type containing 4; FTO: FTO α-ketoglutarate dependent dioxygenase; ALKBH5: alkB homolog 5, RNA demethylase; ALKBH3: alkB homolog 3, RNA demethylase; YTHDC1/2: YTH domain-containing 1/2; YTHDF1/2/3: YTH N6-methyladenosine RNA binding protein 1/2/3; HNRNPA2B1: heterogeneous nuclear ribonucleoprotein A2/B1; HNRNPC/G: heterogeneous nuclear ribonucleoprotein C/G; IGF2BP1/2/3: insulin-like growth factor 2 mRNA-binding protein 1/2/3.
Figure 1

The dynamic modification of m6A. Writers (METTL3, METTL14, WTAP, METTL16, KIAA1429, RBM15/15B, ZFP127, ZC3H13, and ZCCHC4) can identify and methylate the N6 of RNA. Erasers (FTO, ALKBH5, ALKBH3) can catalyze m6A-RNA demethylation. m6A-RNA can be discerned by readers such as YTHDC1 for mRNA splicing. Other readers of m6A are located in the cytoplasm; for instance, YTHDF1, YTHDF2, YTHDF3, YTHDC2, HNRNPA2B1, HNRNPC/G, and IGF2BP1/2/3 are involved in the splicing, processing, translation, and degradation of m6A RNAs. METTL3: methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit; METTL14: methyltransferase 14, N6-adenosine-methyltransferase subunit; METTL16: methyltransferase 16, N6-methyladenosine; WTAP: WT1-associated protein; KIAA1429/VIRMA: vir-like m6A methyltransferase-associated; RBM15/15B: RNA-binding motif protein 15/15B; ZFP127/MKRN3: makorin ring finger protein 3; ZC3H13: zinc finger CCCH-type containing 13; ZCCHC4: zinc finger CCHC-type containing 4; FTO: FTO α-ketoglutarate dependent dioxygenase; ALKBH5: alkB homolog 5, RNA demethylase; ALKBH3: alkB homolog 3, RNA demethylase; YTHDC1/2: YTH domain-containing 1/2; YTHDF1/2/3: YTH N6-methyladenosine RNA binding protein 1/2/3; HNRNPA2B1: heterogeneous nuclear ribonucleoprotein A2/B1; HNRNPC/G: heterogeneous nuclear ribonucleoprotein C/G; IGF2BP1/2/3: insulin-like growth factor 2 mRNA-binding protein 1/2/3.

Writers

“Writers” refer to methyltransferases. Enzymes of this class mainly contain methyltransferase-like 3 (METTL3), methyltransferase-like 14 (METTL14), methyltransferase-like 16 (METTL16), Wilms tumor 1-associated protein (WTAP),[30] vir-like m6A methyltransferase associated (KIAA1429/VIRMA),[31] zinc finger protein (ZFP217),[32] RNA-binding motif protein 15 (RBM15),[33] zinc finger CCCH-type containing 13 (ZC3H13),[34] zinc finger CCHC-type containing 4 (ZCCHC4),[35] and other components. They exist in the form of complexes and jointly catalyze the m6A modification of adenine on RNA. A steady formation can be achieved with METTL3 and METTL14,[36] which catalyze the epigenetic modification of m6A RNA in vitro and in vivo.[37] WTAP has no methyltransferase activity but can bind to METTL3 and METTL14.[38] These three proteins are colocalized in nuclear speckles and play important roles in regulating gene expression and alternative splicing.[39] METTL3, an m6A methyltransferase, also plays a key role in autophagy in non–small-cell lung cancer (NSCLC) cells.[40, 41, 42] This process reverses gefitinib resistance through β-elemene. Compared to paired normal tissues, METTL3 expression was increased in lung adenocarcinoma tissues and participated in gefitinib drug tolerance of NSCLC cells. The key genes in autophagy pathways, such as ATG7 and ATG5, are upregulated by METTL3.[43] The upregulation of inflammatory cytokines, such as tumor necrosis factor α (TNF-α), interleukin 1 beta (IL-1β), interleukin 6 (IL-6), and interleukin 18 (IL-18), and the inflammatory proteins TNF receptor associated factor 6 (TRAF6) and nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (NF-κB) was observed in a microglial inflammation model mediated by lipopolysaccharide (LPS). Surprisingly, METTL3 expression levels were also upregulated alongside TRAF6 in this model. The TRAF6-NF-κB pathway is also activated when METTL3 is overexpressed. Therefore, METTL3 activates the TRAF6-NF-κB pathway and accelerates LPS-induced microglial inflammation.[44]

Erasers

Demethylases, also known as the “erasers,” remove the m6A modification of RNA. This process demonstrates the dynamic and reversible modification of m6A. It has been found that demethylases mainly include the genes Fat Mass and Obesity Associated (FTO)[45] and ALKBH5 (alkane hydroxylase homolog 5).[46] These two molecules are part of the α-ketoglutarate-dependent dioxygenase family.[47] m6A demethylation can be catalyzed in an Fe2+- and α-ketoglutarate-dependent manner.[48] A decrease in FTO and ALKBH5 expression was found to be coupled with an increase in m6A modification in mRNA.[45] FTO is associated with human obesity and is considered an obesity susceptibility gene.[49] It is related to body mass index through energy expenditure and intake.[50] Several studies have revealed that FTO is involved in m6A modifications. m6A demethylation catalyzed by FTO can regulate the stability of mRNA, regulate the efficiency of degradation and translation, and control the expression of protein levels. Research has shown that FTO is necessary for the normal development of the central nervous system[51] and the cardiovascular system.[52] This confirms that mutations in the alkb-related dioxygenase family of genes could cause severe polymalformation syndrome.[53] The Alkb family, which is enriched with iron- and 2-oxoglutarate-dependent nucleic acid oxygenase (NAOX), contains a member named ALKBH5. ALKBH5 catalyzes m6A demethylation.[54] According to a report, the double-stranded β-helix domain of ALKBH5 has a mutual effect on the ATP domain of the DEAD (Asp-Glu-Ala-Asp) box polypeptide 3 (DDX3). This domain participates in critical biological processes, such as the cell cycle, metabolism, and apoptosis.[55] Furthermore, it was revealed that both FTO and ALKBH5 are closely associated with single-nucleotide polymorphisms (SNPs).[56] In addition, it was reported that ALKBH3 could demethylate 1-meA and 3-meC; thus, the damage and incomplete methylation of DNA/RNA could be repaired.[57]

Readers

The major function of m6A-reading proteins is to recognize the bases that have been modified by m6A and to regulate the processing, transportation, translation, and stability of the modified RNA.[58] To date, the m6A reading proteins that have been identified include the YT521-B homology (YTH) family (YTHDF1, YTHDF2, YTHDF3, YTHDC1, and YTHDC2),[59] HNRNP family (HNRNPA2B1, HNRNPC, and HNRNPG),[60, 61, 62] IGF2BP (IGF2BP1, IGF2BP2, and IGF2BP3),[63] and eIF3A/B.[64] The YTHDFs, YTHDC2, IGF2BP, and eIF3A/B proteins are located in the cytoplasm,[65] whereas the YTHDC1 and HNRNP families can be found in the nucleus.[66] YTH N6-methyladenosine RNA-binding protein 2 (YTHDF2) was the first m6A reader to be discovered.[67] YTHDF2 accelerates the degradation of transcripts modified by m6A by directly enlisting the glucose-repressible alcohol dehydrogenase transcriptional effector (CCR4-NOT) deadenylase complex. In contrast, YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) was initially shown to combine with the m6A site near the stop codon and then bind to the translation origination mechanism to enhance the translation efficiency of specific RNA in mammals.[68] YTH N6-methyladenosine RNA-binding protein 3 (YTHDF3) plays a crucial role in the original stages of translation and stability.[69] The YTH domain-containing 1 (YTHDC1) mediates m6A-regulated mRNA splicing,[70] nuclear transport, and gene translation silencing[71] as a nuclear RNA-binding protein.[72] YTH domain-containing 2 (YTHDC2) increases mRNA translation efficiency.[73] HNRNPA2B1 promotes miRNA maturation.[74] Heterogeneous nuclear ribonucleoprotein C (HNRNPC) participates in pre-mRNA processing[75] and alternative splicing.[76] Heterogeneous nuclear ribonucleoprotein G (HNRNPG) regulates alternative splicing and the abundance of target mRNAs.[77] Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs), located in the cytoplasm as m6A readers, preferentially recognize m6A-modified mRNAs. They can reinforce mRNA stability and promote translational efficiency.[78]

m6A RNA methylation and pathological cardiac remodeling

Cardiac remodeling includes changes in genomic expression, molecules, cells, and the mesenchyme that clinically manifest as changes in cardiac size, shape, and function after injury.[79] Cardiac remodeling can be categorized into physiological remodeling and pathological remodeling. Physiological cardiac remodeling is often caused by exercise or pregnancy.[80] It manifests as a slight (15%) increase in heart weight and an increase in the length and width of individual cardiomyocytes. The shape of the heart is normal, which is beneficial to its function.[81] However, pathological cardiac hypertrophy can manifest as changes in cardiac gene expression, cell death, fibrosis, Ca2+ transport regulatory protein disorders,[9] mitochondrial dysfunction, metabolic maladjustment, restoration of antenatal gene expression, damaged protein quality assurance mechanisms, changes in sarcomere structure, and lack of angiogenesis.[82] The signaling mechanism inducing these reactions promotes maladaptive cardiac remodeling and dysfunction, eventually leading to heart failure (HF).[83] It has been reported that heart failure (HF) is a chronic disease that inflicts more than 20 million patients worldwide.[84,85] In the past several years, a growing number of studies have revealed the relationship between m6A modifications and cardiovascular diseases, including cardiac hypertrophy,[86] heart failure,[19] atherosclerosis, coronary heart disease,[87] ischemic cardiomyopathy, hypertension, and vascular disease.[88] Therefore, inhibiting concurrent signaling pathways will have important therapeutic significance for interventions in these cardiac diseases.

Cardiac hypertrophy

In the presence of hemodynamic stress, cardiomyocytes adapt by becoming hypertrophic. This reaction plays a reparative role in improving cardiac function, decreasing the strain on the ventricular wall and oxygen expenditure.[89] Cardiac hypertrophy can be divided into two types: physiological and pathological. Physiological cardiac hypertrophy, which can maintain normal morphology and play a beneficial role in the heart, mostly results from exercise training or pregnancy.[90] In contrast, pathological cardiac hypertrophy causes many cardiovascular pathophysiological changes, such as ventricular remodeling, fibrosis, and cardiac gene expression alteration.[91]

Hinger et al.[92] found an increase in m6A content in human heart failure samples but showed a preserved distribution. The protein level of METTL3 was increased, and that of FTO was decreased, while there was no change in ALKBH5 levels. Afterward, human and hypertrophic neonatal rat ventricular myocytes obtained from heart failure samples were used to investigate whether there was conserved specificity in m6A events in cardiomyocytes across species. Their results showed stress-responsive m6A-transcripts between rats and humans were conservative. In both human hearts and rat cardiomyocytes, Western blotting showed that coronin 6 (CORO6) levels were reduced, whereas the expression of RE1 silencing transcription factor (REST) was increased. However, the mRNA levels of these two genes remained unaffected. Furthermore, they detected m6A content in both human heart failure samples and hypertrophic cardiomyocytes. They found that REST expression was increased, while CORO6 had greater m6A content in nonfailing heart and normal cardiomyocytes. Upon upregulation of METTL3, the translation levels of REST and CORO6 increased. Hence, posttranscriptional modifications may play a direct role in gene expression in cardiomyocytes.

Gao et al.[93] revealed a piRNA (PIWI-interacting RNA) named CHAPIR (cardiac-hypertrophy-associated piRNA), which regulates cardiac hypertrophy. Overexpression of CHAPIR using a mimic aggravated pathological hypertrophic response in a TAC mouse model, while the downregulation of CHAPIR notably attenuated cardiac hypertrophy and recovered cardiac function. In terms of mechanism, METTL3 combined with CHAPIR–PIWIL4 complexes suppressed Parp10 mRNA m6A methylation. The mRNA and protein expression levels of poly(ADP-ribose) polymerase family member 10 (PARP10) increased, which promoted mono-ADP-ribosylation of GSK3β and suppressed its kinase activity.[94] This process increased nuclear NFATC4 levels and led to the progression of pathological hypertrophy. Therefore, targeting the CHAPIRMETTL3-PARP10-NFATC4 signaling axis could be a therapeutic mechanism for improving cardiac hypertrophy.

Dorn et al.[95] discovered that the extent of m6A methylation increases in response to hypertrophic stimulation. The growth of hypertrophic cardiomyocytes was fully abolished upon stimulation, and they did not undergo hypertrophy when METTL3 was suppressed in vitro. However, the overexpression of METTL3 can cause spontaneous and compensatory hypertrophy. In vivo, cardiac-specific METTL3-knockout mice showed cardiac remodeling and heart failure followed by cardiac homeostasis disorders, whereas increased METTL3 levels caused cardiac hypertrophy.

Kmietczyk et al.[96] showed that the mechanism of m6A RNA methylation is dynamic and effective in cardiomyocytes undergoing pressure[97] and regulates gene expression and cellular proliferation in the heart. They found that METTL3 and FTO could participate in m6A RNA methylation by influencing transcript stability and regulating translational efficiency. In an in vitro model of neonatal rat cardiomyocytes (NRCM), the knockdown of METTL3 reduced m6A levels[98] and increased the cell size and the expression of the hypertrophic markers ANP and BNP. However, FTO-KO mice exhibited enhanced m6A levels and weakened NRCM hypertrophy. In an in vivo model of AAV9-mediated METTL3 overexpression in C57Bl6/N mice and TAC mice, METTL3 overexpression shrank the cross-sectional area of the myocytes and suppressed pathological hypertrophic cellular growth. Nevertheless, how METTL3 and FTO regulate gene expression and cellular growth and which specific target genes play an essential role in cardiomyocyte hypertrophy are still under study.

Heart failure

Berulava et al.[99] discovered that the level of m6A RNA methylation decreases during heart failure. The mRNA level of calmodulin 1 (calm1) remained unchanged, while the protein expression level of calm1 was reduced. In other words, m6A RNA methylation levels influenced protein levels rather than mRNA levels. m6A RNA methylation is directly proportional to ribosomal occupancy, indicating increased protein levels of hypermethylated transcripts and decreased protein levels of hypomethylated transcripts. A worsened cardiac phenotype in the FTO-knockout mice model after TAC was also observed, as the ejection fraction was reduced and the degree of dilatation was increased.

Mathiyalagan et al.[100] discovered that the demethylase FTO was associated with cardiac function during cardiac remodeling and repair. They detected reduced FTO expression levels in failing mammalian hearts and hypoxic cardiomyocytes; therefore, m6A RNA methylation increased. Sarco/endoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) is a contractile protein that exhibits less stability and lower efficiency to regulate translation when hypermethylated, eventually resulting in cardiomyocyte contractile function. However, FTO overexpression in human myocytes led to SERCA2a demethylation. Furthermore, cardiac contractile function improved with an increase in SERCA2a expression. They also found that FTO overexpression reduced fibrosis and promoted angiogenesis in mouse models of myocardial infarction. Hence, this mechanism provides novel insights into cardiac remodeling and repair.

Research progress on new techniques in detecting m6A RNA methylation

Researchers are actively exploring the role of m6A modification-related molecules in cardiovascular disease; however, many problems and challenges still need to be resolved. For example, transcriptome-wide mapping used in m6A can help us better understand catalog m6A targets and reveal the underlying epigenetic modification mechanisms. In 2012, Nature and Cell published a method for the whole transcriptome sequencing of m6A modification via m6A-specific antibody enrichment (MeRIP-seq or m6A-seq);[19,101] however, MeRIP-seq has an insufficient resolution (about 100 nt). However, insurmountable weaknesses in principle, such as low repeatability, large sample demand, and cumbersome operation, have caused significant problems in m6A research in recent years.

In 2015, Nature Methods proposed a new method for the high-resolution detection of the localization of N6-methyladenosine in eukaryotic RNA called m6A single-nucleotide resolution cross-linking and immunoprecipitation (miCLIP).[102] Mutations would occur when the cross-linking of the RNA-m6A antibody-binding sites is reverse-transcribed. The mutated sequences had unique features (e.g., C-T transition or truncation) that could pinpoint m6A. miCLIP can perform high-resolution detection of individual m6A residues and m6A cluster analysis of the total RNA. In particular, miCLIP is suitable for small nucleolar RNA (snoRNA).

In a recent study, Zhang et al. published a research paper titled “Single-base mapping of m6A by an antibody-independent method,”[103] which described a new principle of m6A detection technology named m6A-REF-seq (m6A-sensitive RNA-endoribonuclease-facilitated sequencing). This technology used the sensitivity of the newly discovered RNA endonuclease to m6A, which eliminated the dependence of traditional methods on antibodies and achieved accurate detection of m6A across the transcriptome.[104] New methods must be implemented in the m6A field with the development of better scientific methods and technological advances. However, whether other types of m6A modification have some links to cardiac remodeling is still to be discovered. Finally, drugs targeting m6A are promising for the clinical treatment of cardiovascular diseases.

We hope that consistent studies in this field can further deepen our understanding of the processes surrounding heart failure and approach the reality of discovering new treatments, thereby improving the quality of life of patients with heart failure.

Conclusions and future perspectives

The most abundant RNA modification in RNA epigenetics is m6A methylation.[105] m6A methylation studies have currently gained significant popularity in scientific research.[106] In this review, we focused on cardiac remodeling, summarized the classification of m6A RNA methylases, and discussed their dynamic modification (Figure 1) in detail. Furthermore, we surveyed m6A RNA modifications in cardiac remodeling, including cardiac hypertrophy and heart failure (Table 1). The mechanisms regarding the development of cardiac hypertrophy are intricate; however, what we currently know is just the tip of the iceberg, and further research is needed to elucidate the epigenetic mechanisms underlying heart failure.[107] In the past few years, we have opened new areas for advancing the known mechanisms and identifying the unknown pathways involved in cardiac remodeling. Heart failure is still difficult to cure in the clinical setting and its prevalence rate increases with age.[108] m6A has potential applications in the diagnosis and treatment of heart failure. Research focus should be placed on the abnormal expression of some m6A enzymes, such as METTL3 and FTO, because they are related to cardiac hypertrophy or heart failure since the early detection of these abnormalities will help in the early diagnosis of heart failure. It is also possible that we interfere with the expression of methylases, such as METTL3 and FTO, to prevent heart failure.

Table 1

m6A and cardiac remodeling

Types of cardiac remodeling Effector Type of effector Expression Target genes Mechanism Reference
Cardiac METTL3 Writer Upregulation REST Protein expression was higher in condition of greater [92]
hypertrophy FTO Eraser Downregulation CORO6 m6A content, and overexpression of METTL3 was sufficient to positively affect the translation of REST and CORO6
METTL3 Writer Reduce activity of METTL3 PARP10 CHAPIR-PIWIL4 → METTL3 → m6A-PARP10 → PARP10 (mRNA and protein) → mono-ADP-ribosylation of GSK3β → GSK3β kinase activity → NFATC4 → pathological hypertrophy [93]
METTL3 Writer Upregulation MAP3K6/ In vitro: METTL3 → prevent pathological hypertrophy [95]
MAP4K5/ MAPK14/ Nppa/Nppb METTL3 → spontaneous and compensate hypertrophy In vivo: METTL3-KO → remodeling and heart failure → cardiac homeostasis disorder METTL3 → cardiac hypertrophy
METTL3 Writer Downregulation Unknown In vitro: METTL3-KO → m6A level → cell size and level of Nppa/Nppb; FTO-KO → m6A level → hypertrophy of NRCM In vivo: METTL3-overexpression → myocytes cross-sectional area → pathological hypertrophic cellular growth [96]
Heart failure FTO Eraser Downregulation Calm1 Calm1 protein expression regulation in heart failure occurs partially only on translational level and without changes in DNA to RNA transcription [99]
FTO Eraser Downregulation SERCA2a In failing mammalian hearts and hypoxic cardiomyocyte, FTO SERCA2a mRNA is hypermethylated cardiomyocytes contractile function [100]

  1. METTL3: methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit; REST: RE1 silencing transcription factor; CORO6: coronin 6; PARP10: poly (ADP-ribose) polymerase family member 10; MAP3K6/5/14: mitogen-activated protein kinase kinase kinase 6/5/14; Nppa: natriuretic peptide A; Nppb: natriuretic peptide B; FTO: FTO α-ketoglutarate-dependent dioxygenase; Calm1: calmodulin 1; SERCA2a: sarco/endoplasmic reticulum Ca2+-ATPase.

Department of Cardiology, the First Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province, China.

  1. Source of Funding

    This study was funded by the National Natural Science Foundation of China (No. 8197021725) and the Shenyang Science and Technology Project (No. 19-112-4-003).

  2. Conflict of Interest

    Yingxian Sun is an Associate-Editor-in-Chief of the journal. The article was subject to the journal's standard procedures, and peer review was handled independently of this editor and his research groups.

References

1 De Backer G. Epidemiology and prevention of cardiovascular disease: Quo vadis? Eur J Prev Cardiol 2017;24:768–72.10.1177/2047487317691875Search in Google Scholar PubMed

2 Wang Y, Chen J, Cowan DB, Wang DZ. Noncoding RNAs in cardiac regeneration: Mechanism of action and therapeutic potential. Semin Cell Dev Biol 2021;118:150–62.10.1016/j.semcdb.2021.07.007Search in Google Scholar PubMed PubMed Central

3 Duan B. Concise Review: Harnessing iPSC-derived Cells for Ischemic Heart Disease Treatment. J Transl Intern Med 2020;8:20–5.10.2478/jtim-2020-0004Search in Google Scholar PubMed PubMed Central

4 Saliba LJ, Maffett S. Hypertensive Heart Disease and Obesity: A Review. Heart Fail Clin 2019;15:509–17.10.1016/j.hfc.2019.06.003Search in Google Scholar PubMed

5 Ciarambino T, Menna G, Sansone G, Giordano M. Cardiomyopathies: An Overview. Int J Mol Sci 2021;22:7722.10.3390/ijms22147722Search in Google Scholar PubMed PubMed Central

6 Gedela M, Khan M, Jonsson O. Heart Failure. SD Med 2015;68:403–5, 407–9.Search in Google Scholar

7 Li C, Wang DW, Zhao C. Cardiovascular Involvement in Patients with 2019 Novel Coronavirus Disease. J Transl Intern Med 2021;9:152–60.10.2478/jtim-2021-0016Search in Google Scholar PubMed PubMed Central

8 Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, et al. Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors. Circ Res 2017;121:677–94.10.1161/CIRCRESAHA.117.308903Search in Google Scholar PubMed

9 Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol 2018;15:387–407.10.1038/s41569-018-0007-ySearch in Google Scholar PubMed

10 Oldfield CJ, Duhamel TA, Dhalla NS. Mechanisms for the transition from physiological to pathological cardiac hypertrophy. Can J Physiol Pharmacol 2020;98:74–84.10.1139/cjpp-2019-0566Search in Google Scholar PubMed

11 Li Y, Liang Y, Zhu Y, Zhang Y, Bei Y. Noncoding RNAs in Cardiac Hypertrophy. J Cardiovasc Transl Res 2018;11:439–49.10.1007/s12265-018-9797-xSearch in Google Scholar PubMed

12 Boccaletto P, Machnicka MA, Purta E, Piatkowski P, Baginski B, Wirecki TK, et al. MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res 2018;46:303–7.10.1093/nar/gkx1030Search in Google Scholar PubMed PubMed Central

13 Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA Modifications in Gene Expression Regulation. Cell 2017;169:1187–200.10.1016/j.cell.2017.05.045Search in Google Scholar PubMed PubMed Central

14 Zhu M, Ding Q, Lin Z, Chen X, Chen S, Zhu Y. New insights of epigenetics in vascular and cellular senescence. J Transl Intern Med 2021;9:239–48.10.2478/jtim-2021-0049Search in Google Scholar PubMed PubMed Central

15 Ma CJ, Ding JH, Ye TT, Yuan BF, Feng YQ. AlkB Homologue 1 Demethylates N(3)-Methylcytidine in mRNA of Mammals. ACS Chem Biol 2019;14:1418–25.10.1021/acschembio.8b01001Search in Google Scholar PubMed

16 Cockman E, Anderson P, Ivanov P. TOP mRNPs: Molecular Mechanisms and Principles of Regulation. Biomolecules 2020;10:969.10.3390/biom10070969Search in Google Scholar PubMed PubMed Central

17 Karthiya R, Wasil SM, Khandelia P. Emerging role of N4-acetylcytidine modification of RNA in gene regulation and cellular functions. Mol Biol Rep 2020;47:9189–99.10.1007/s11033-020-05963-wSearch in Google Scholar PubMed

18 Wiener D, Schwartz S. The epitranscriptome beyond m6A. Nat Rev Genet 2021;22:119–31.10.1038/s41576-020-00295-8Search in Google Scholar PubMed

19 Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell 2012;149:1635–46.10.1016/j.cell.2012.05.003Search in Google Scholar PubMed PubMed Central

20 Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomed Pharmacother 2019;112:108613.10.1016/j.biopha.2019.108613Search in Google Scholar PubMed

21 Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, et al. m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. Cancer Cell 2017;31:591–606.10.1016/j.ccell.2017.02.013Search in Google Scholar PubMed PubMed Central

22 Li Y, Wu K, Quan W, Yu L, Chen S, Cheng C, et al. The dynamics of FTO binding and demethylation from the m6A motifs. RNA Biol 2019;16:1179–89.10.1080/15476286.2019.1621120Search in Google Scholar PubMed PubMed Central

23 Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 2012;485:201–6.10.1038/nature11112Search in Google Scholar PubMed

24 Ma S, Chen C, Ji X, Liu J, Zhou Q, Wang G, et al. The interplay between m6A RNA methylation and noncoding RNA in cancer. J Hematol Oncol 2019;12:121.10.1186/s13045-019-0805-7Search in Google Scholar PubMed PubMed Central

25 He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer 2019;18:176.10.1186/s12943-019-1109-9Search in Google Scholar PubMed PubMed Central

26 Tong J, Flavell RA, Li HB. RNA m6A modification and its function in diseases. Front Med 2018;12:481–9.10.1007/s11684-018-0654-8Search in Google Scholar PubMed

27 Chen J, Wei X, Yi X, Jiang DS. RNA Modification by m6A Methylation in Cardiovascular Disease. Oxid Med Cell Longev 2021;2021:8813909.10.1155/2021/8813909Search in Google Scholar PubMed PubMed Central

28 Li LJ, Fan YG, Leng RX, Pan HF, Ye DQ. Potential link between m6A modification and systemic lupus erythematosus. Mol Immunol 2018;93:55–63.10.1016/j.molimm.2017.11.009Search in Google Scholar PubMed

29 Zhang W, Qian Y, Jia G. The detection and functions of RNA modification m6A based on m6A writers and erasers. J Biol Chem 2021;297:100973.10.1016/j.jbc.2021.100973Search in Google Scholar PubMed PubMed Central

30 Reichel M, Köster T, Staiger D. Marking RNA: m6A writers, readers, and functions in Arabidopsis. J Mol Cell Biol 2019;11:899–910.10.1093/jmcb/mjz085Search in Google Scholar PubMed PubMed Central

31 Zhu W, Wang JZ, Wei JF, Lu C. Role of m6A methyltransferase component VIRMA in multiple human cancers (Review). Cancer Cell Int 2021;21:172.10.1186/s12935-021-01868-1Search in Google Scholar PubMed PubMed Central

32 Liu Q, Zhao Y, Wu R, Jiang Q, Cai M, Bi Z, et al. ZFP217 regulates adipogenesis by controlling mitotic clonal expansion in a METTL3-m6A dependent manner. RNA Biol 2019;16:1785–93.10.1080/15476286.2019.1658508Search in Google Scholar PubMed PubMed Central

33 Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 2014;505:117–20.10.1038/nature12730Search in Google Scholar PubMed PubMed Central

34 Knuckles P, Lence T, Haussmann IU, Jacob D, Kreim N, Carl SH, et al. Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m6A machinery component Wtap/Fl(2)d. Genes Dev 2018;32:415–29.10.1101/gad.309146.117Search in Google Scholar PubMed PubMed Central

35 Ma H, Wang X, Cai J, Dai Q, Natchiar SK, Lv R, et al. N(6-) Methyladenosine methyltransferase ZCCHC4 mediates ribosomal RNA methylation. Nat Chem Biol 2019;15:88–94.10.1038/s41589-018-0184-3Search in Google Scholar PubMed PubMed Central

36 Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol 2014;10:93–5.10.1038/nchembio.1432Search in Google Scholar PubMed PubMed Central

37 Wang P, Doxtader KA, Nam Y. Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases. Mol Cell 2016;63:306–17.10.1016/j.molcel.2016.05.041Search in Google Scholar PubMed PubMed Central

38 Selberg S, Žusinaite E, Herodes K, Seli N, Kankuri E, Merits A, et al. HIV Replication Is Increased by RNA Methylation METTL3/METTL14/ WTAP Complex Activators. ACS Omega 2021;6:15957–63.10.1021/acsomega.1c01626Search in Google Scholar PubMed PubMed Central

39 Ping XL, Sun BF, Wang L, Xiao W, Yang X, Wang WJ, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res 2014;24:177–89.10.1038/cr.2014.3Search in Google Scholar PubMed PubMed Central

40 Zhang Y, Liu S, Zhao T, Dang C. METTL3‑mediated m6A modification of Bcl-2 mRNA promotes non‑small cell lung cancer progression. Oncol Rep 2021;46:163.10.3892/or.2021.8114Search in Google Scholar PubMed PubMed Central

41 Li M, Wang Q, Zhang X, Yan N, Li X. CircPUM1 promotes cell growth and glycolysis in NSCLC via upregulating METTL3 expression through miR-590-5p. Cell Cycle 2021;20:1279–94.10.1080/15384101.2021.1934625Search in Google Scholar PubMed PubMed Central

42 Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, et al. m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol 2021;14:32.10.1186/s13045-021-01048-8Search in Google Scholar PubMed PubMed Central

43 Liu S, Li Q, Li G, Zhang Q, Zhuo L, Han X, et al. The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene. Cell Death Dis 2020;11:969.10.1038/s41419-020-03148-8Search in Google Scholar PubMed PubMed Central

44 Wen L, Sun W, Xia D, Wang Y, Li J, Yang S. The m6A methyltransferase METTL3 promotes LPS-induced microglia inflammation through TRAF6/NF-κB pathway. Neuroreport 2022;33:243–51.10.1097/WNR.0000000000001550Search in Google Scholar PubMed

45 Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol 2011;7:885–7.10.1038/nchembio.687Search in Google Scholar PubMed PubMed Central

46 Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell 2013;49:18–29.10.1016/j.molcel.2012.10.015Search in Google Scholar PubMed PubMed Central

47 Wu G, Yan Y, Cai Y, Peng B, Li J, Huang J, et al. ALKBH1-8 and FTO: Potential Therapeutic Targets and Prognostic Biomarkers in Lung Adenocarcinoma Pathogenesis. Front Cell Dev Biol 2021;9:633927.10.3389/fcell.2021.633927Search in Google Scholar PubMed PubMed Central

48 Huo FC, Zhu ZM, Pei DS. N(6) -methyladenosine (m(6) A) RNA modification in human cancer. Cell Prolif 2020;53:e12921.10.1111/cpr.12921Search in Google Scholar PubMed PubMed Central

49 Zhou Y, Hambly BD, McLachlan CS. FTO associations with obesity and telomere length. J Biomed Sci 2017;24:65.10.1186/s12929-017-0372-6Search in Google Scholar PubMed PubMed Central

50 Yuzbashian E, Asghari G, Chan CB, Hedayati M, Safarian M, Zarkesh M, et al. The association of dietary and plasma fatty acid composition with FTO gene expression in human visceral and subcutaneous adipose tissues. Eur J Nutr 2021;60:2485–94.10.1007/s00394-020-02422-xSearch in Google Scholar PubMed

51 Pan T, Wu F, Li L, Wu S, Zhou F, Zhang P, et al. The role m6A RNA methylation is CNS development and glioma pathogenesis. Mol Brain 2021;14:119.10.1186/s13041-021-00831-5Search in Google Scholar PubMed PubMed Central

52 Liu C, Mou S, Pan C. The FTO gene rs9939609 polymorphism predicts risk of cardiovascular disease: a systematic review and meta-analysis. PLoS One 2013;8:e71901.10.1371/journal.pone.0071901Search in Google Scholar PubMed PubMed Central

53 Boissel S, Reish O, Proulx K, Kawagoe-Takaki H, Sedgwick B, Yeo GS, et al. Loss-of-function mutation in the dioxygenase-encoding FTO gene causes severe growth retardation and multiple malformations. Am J Hum Genet 2009;85:106–11.10.1016/j.ajhg.2009.06.002Search in Google Scholar PubMed PubMed Central

54 Zhou B, Han Z. Crystallization and preliminary X-ray diffraction of the RNA demethylase ALKBH5. Acta Crystallogr Sect F Struct Biol Cryst Commun 2013;69:1231–4.10.1107/S1744309113024858Search in Google Scholar PubMed PubMed Central

55 Shah A, Rashid F, Awan HM, Hu S, Wang X, Chen L, et al. The DEAD-Box RNA Helicase DDX3 Interacts with m6A RNA Demethylase ALKBH5. Stem Cells Int 2017;2017:8596135.10.1155/2017/8596135Search in Google Scholar PubMed PubMed Central

56 Piette ER, Moore JH. Identification of epistatic interactions between the human RNA demethylases FTO and ALKBH5 with gene set enrichment analysis informed by differential methylation. BMC Proc 2018;12:59.10.1186/s12919-018-0122-0Search in Google Scholar PubMed PubMed Central

57 Ueda Y, Ooshio I, Fusamae Y, Kitae K, Kawaguchi M, Jingushi K, et al. AlkB homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells. Sci Rep 2017;7:42271.10.1038/srep42271Search in Google Scholar PubMed PubMed Central

58 Patil DP, Pickering BF, Jaffrey SR. Reading m6A in the Transcriptome: m6A-Binding Proteins. Trends Cell Biol 2018;28:113–27.10.1016/j.tcb.2017.10.001Search in Google Scholar PubMed PubMed Central

59 Xu C, Wang X, Liu K, Roundtree IA, Tempel W, Li Y, et al. Structural basis for selective binding of m6A RNA by the YTHDC1 YTH domain. Nat Chem Biol 2014;10:927–9.10.1038/nchembio.1654Search in Google Scholar PubMed

60 Alarcón CR, Goodarzi H, Lee H, Liu X, Tavazoie S, Tavazoie SF. HNRNPA2B1 Is a Mediator of m6A-Dependent Nuclear RNA Processing Events. Cell 2015;162:1299–308.10.1016/j.cell.2015.08.011Search in Google Scholar PubMed PubMed Central

61 Zarnack K, König J, Tajnik M, Martincorena I, Eustermann S, Stévant I, et al. Direct competition between hnRNP C and U2AF65 protects the transcriptome from the exonization of Alu elements. Cell 2013;152:453–66.10.1016/j.cell.2012.12.023Search in Google Scholar PubMed PubMed Central

62 Zhou KI, Shi H, Lyu R, Wylder AC, Matuszek Ż, Pan JN, et al. Regulation of Co-transcriptional Pre-mRNA Splicing by m6A through the Low-Complexity Protein hnRNPG. Mol Cell 2019;76:70–81.10.1016/j.molcel.2019.07.005Search in Google Scholar PubMed PubMed Central

63 Huang X, Zhang H, Guo X, Zhu Z, Cai H, Kong X. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer. J Hematol Oncol 2018;11:88.10.1186/s13045-018-0628-ySearch in Google Scholar PubMed PubMed Central

64 Shi H, Chai P, Jia R, Fan X. Novel insight into the regulatory roles of diverse RNA modifications: Re-defining the bridge between transcription and translation. Mol Cancer 2020;19:78.10.1186/s12943-020-01194-6Search in Google Scholar PubMed PubMed Central

65 Liu N, Pan T. N6-methyladenosine–encoded epitranscriptomics. Nat Struct Mol Biol 2016;23:98–102.10.1038/nsmb.3162Search in Google Scholar PubMed

66 Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res 2018;28:616–24.10.1038/s41422-018-0040-8Search in Google Scholar PubMed PubMed Central

67 Wang JY, Lu AQ. The biological function of m6A reader YTHDF2 and its role in human disease. Cancer Cell Int 2021;21:109.10.1186/s12935-021-01807-0Search in Google Scholar PubMed PubMed Central

68 Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, et al. N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell 2015;161:1388–99.10.1016/j.cell.2015.05.014Search in Google Scholar PubMed PubMed Central

69 Li A, Chen YS, Ping XL, Yang X, Xiao W, Yang Y, et al. Cytoplasmic m6A reader YTHDF3 promotes mRNA translation. Cell Res 2017;27:444–7.10.1038/cr.2017.10Search in Google Scholar PubMed PubMed Central

70 Wu S, Zhang S, Wu X, Zhou X. m6A RNA Methylation in Cardiovascular Diseases. Mol Ther 2020;28:2111–9.10.1016/j.ymthe.2020.08.010Search in Google Scholar PubMed PubMed Central

71 Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttman M, et al. m6A RNA methylation promotes XIST-mediated transcriptional repression. Nature 2016;537:369–73.10.1038/nature19342Search in Google Scholar PubMed PubMed Central

72 Roundtree IA, He C. Nuclear m6A Reader YTHDC1 Regulates mRNA Splicing. Trends Genet 2016;32:320–1.10.1016/j.tig.2016.03.006Search in Google Scholar PubMed

73 Hsu PJ, Zhu Y, Ma H, Guo Y, Shi X, Liu Y, et al. Ythdc2 is an N(6)-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res 2017;27:1115–27.10.1038/cr.2017.99Search in Google Scholar PubMed PubMed Central

74 Alarcón CR, Lee H, Goodarzi H, Halberg N, Tavazoie SF. N6-methyladenosine marks primary microRNAs for processing. Nature 2015;519:482–5.10.1038/nature14281Search in Google Scholar PubMed PubMed Central

75 Cieniková Z, Damberger FF, Hall J, Allain FH, Maris C. Structural and mechanistic insights into poly(uridine) tract recognition by the hnRNP C RNA recognition motif. J Am Chem Soc 2014;136:14536–44.10.1021/ja507690dSearch in Google Scholar PubMed

76 Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature 2015;518:560–4.10.1038/nature14234Search in Google Scholar PubMed PubMed Central

77 Liu N, Zhou KI, Parisien M, Dai Q, Diatchenko L, Pan T. N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. Nucleic Acids Res 2017;45:6051–63.10.1093/nar/gkx141Search in Google Scholar PubMed PubMed Central

78 Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol 2018;20:28595.10.1038/s41556-018-0045-zSearch in Google Scholar PubMed PubMed Central

79 Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569–82.10.1016/S0735-1097(99)00630-0Search in Google Scholar PubMed

80 Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008;358:1370-80.10.1056/NEJMra072139Search in Google Scholar PubMed

81 Bernardo BC, McMullen JR. Molecular Aspects of Exercise-induced Cardiac Remodeling. Cardiol Clin 2016;34:515–30.10.1016/j.ccl.2016.06.002Search in Google Scholar PubMed

82 Wu QQ, Xiao Y, Yuan Y, Ma ZG, Liao HH, Liu C, et al. Mechanisms contributing to cardiac remodelling. Clin Sci (Lond) 2017;131:2319–45.10.1042/CS20171167Search in Google Scholar PubMed

83 Tham YK, Bernardo BC, Ooi JY, Weeks KL, McMullen JR. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol 2015;89:1401–38.10.1007/s00204-015-1477-xSearch in Google Scholar PubMed

84 Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 2014;35:2950–9.10.1093/eurheartj/ehu299Search in Google Scholar PubMed

85 Kapiloff MS, Emter CA. The cardiac enigma: current conundrums in heart failure research. F1000Res 2016;5:F1000 Faculty Rev-72.10.12688/f1000research.7278.1Search in Google Scholar PubMed PubMed Central

86 Fedeles BI, Singh V, Delaney JC, Li D, Essigmann JM. The AlkB Family of Fe(II)/α-Ketoglutarate-dependent Dioxygenases: Repairing Nucleic Acid Alkylation Damage and Beyond. J Biol Chem 2015;290:20734–42.10.1074/jbc.R115.656462Search in Google Scholar PubMed PubMed Central

87 Wu Y, Zhan S, Xu Y, Gao X. RNA modifications in cardiovascular diseases, the potential therapeutic targets. Life Sci 2021;278:119565.10.1016/j.lfs.2021.119565Search in Google Scholar PubMed

88 Paramasivam A, Vijayashree Priyadharsini J, Raghunandhakumar S. N6-adenosine methylation (m6A): a promising new molecular target in hypertension and cardiovascular diseases. Hypertens Res 2020;43:153–4.10.1038/s41440-019-0338-zSearch in Google Scholar PubMed

89 Berenji K, Drazner MH, Rothermel BA, Hill JA. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 2005;289:h8–h16.10.1152/ajpheart.01303.2004Search in Google Scholar PubMed

90 Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 2010;128:191–227.10.1016/j.pharmthera.2010.04.005Search in Google Scholar PubMed

91 Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol 2016;97:245–62.10.1016/j.yjmcc.2016.06.001Search in Google Scholar PubMed

92 Hinger SA, Wei J, Dorn LE, Whitson BA, Janssen PML, He C, et al. Remodeling of the m6A landscape in the heart reveals few conserved post-transcriptional events underlying cardiomyocyte hypertrophy. J Mol Cell Cardiol 2021;151:46–55.10.1016/j.yjmcc.2020.11.002Search in Google Scholar PubMed PubMed Central

93 Gao XQ, Zhang YH, Liu F, Ponnusamy M, Zhao XM, Zhou LY, et al. The piRNA CHAPIR regulates cardiac hypertrophy by controlling METTL3-dependent N(6)-methyladenosine methylation of Parp10 mRNA. Nat Cell Biol 2020;22:1319–31.10.1038/s41556-020-0576-ySearch in Google Scholar PubMed

94 Huang B, Ding C, Zou Q, Wang W, Li H. Cyclophosphamide Regulates N6-Methyladenosine and m6A RNA Enzyme Levels in Human Granulosa Cells and in Ovaries of a Premature Ovarian Aging Mouse Model. Front Endocrinol (Lausanne) 2019;10:415.10.3389/fendo.2019.00415Search in Google Scholar PubMed PubMed Central

95 Dorn LE, Lasman L, Chen J, Xu X, Hund TJ, Medvedovic M, et al. The N(6)-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy. Circulation 2019;139:533–45.10.1161/CIRCULATIONAHA.118.036146Search in Google Scholar PubMed PubMed Central

96 Kmietczyk V, Riechert E, Kalinski L, Boileau E, Malovrh E, Malone B, et al. m6A-mRNA methylation regulates cardiac gene expression and cellular growth. Life Sci Alliance 2019;2:e201800233.10.26508/lsa.201800233Search in Google Scholar PubMed PubMed Central

97 Zhou Y, Kong Y, Fan W, Tao T, Xiao Q, Li N, et al. Principles of RNA methylation and their implications for biology and medicine. Biomed Pharmacother 2020;131:110731.10.1016/j.biopha.2020.110731Search in Google Scholar PubMed

98 Dai D, Wang H, Zhu L, Jin H, Wang X. N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis 2018;9:124.10.1038/s41419-017-0129-xSearch in Google Scholar PubMed PubMed Central

99 Berulava T, Buchholz E, Elerdashvili V, Pena T, Islam MR, Lbik D, et al. Changes in m6A RNA methylation contribute to heart failure progression by modulating translation. Eur J Heart Fail 2020;22:54–66.10.1002/ejhf.1672Search in Google Scholar PubMed

100 Mathiyalagan P, Adamiak M, Mayourian J, Sassi Y, Liang Y, Agarwal N, et al. FTO-Dependent N(6)-Methyladenosine Regulates Cardiac Function During Remodeling and Repair. Circulation 2019;139:518–532.10.1161/CIRCULATIONAHA.118.033794Search in Google Scholar PubMed PubMed Central

101 Zhang C, Chen Y, Sun B, Wang L, Yang Y, Ma D, et al. m6A modulates haematopoietic stem and progenitor cell specification. Nature 2017;549:273–6.10.1038/nature23883Search in Google Scholar PubMed

102 Linder B, Grozhik AV, Olarerin-George AO, Meydan C, Mason CE, Jaffrey SR. Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods 2015;12:767–72.10.1038/nmeth.3453Search in Google Scholar PubMed PubMed Central

103 Zhang Z, Chen LQ, Zhao YL, Yang CG, Roundtree IA, Zhang Z, et al. Single-base mapping of m6A by an antibody-independent method. Sci Adv 2019;5:eaax0250.10.1101/575555Search in Google Scholar

104 Gao Y, Liu X, Wu B, Wang H, Xi F, Kohnen MV, et al. Quantitative profiling of N(6)-methyladenosine at single-base resolution in stem-differentiating xylem of Populus trichocarpa using Nanopore direct RNA sequencing. Genome Biol 2021;22:22.10.1186/s13059-020-02241-7Search in Google Scholar PubMed PubMed Central

105 Meyer KD, Jaffrey SR. Rethinking m6A Readers, Writers, and Erasers. Annu Rev Cell Dev Biol 2017;33:319–42.10.1146/annurev-cellbio-100616-060758Search in Google Scholar PubMed PubMed Central

106 Liu ZX, Li LM, Sun HL, Liu SM. Link Between m6A Modification and Cancers. Front Bio Biotechnol 2018;6:89.10.3389/fbioe.2018.00089Search in Google Scholar PubMed PubMed Central

107 Morissens M, Besse-Hammer T, Azerad MA, Efira A, Rodriguez JC. Evaluation of Cardiac Function in Patients with Sickle Cell Disease with Left Ventricular Global Longitudinal Strain. J Transl Intern Med 2020;8:41–7.10.2478/jtim-2020-0007Search in Google Scholar PubMed PubMed Central

108 Xu S, Qiu Y, Tao J. The challenges and optimization of cell-based therapy for cardiovascular disease. J Transl Intern Med 2021;9:234–8.10.2478/jtim-2021-0017Search in Google Scholar PubMed PubMed Central

Published Online: 2023-01-05

© 2022 Yiqing Yang, Mbikyo B Muisha, Junzhe Zhang, Yingxian Sun, Zhao Li, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Articles in the same Issue

  1. Editorial
  2. Interpretation of the key issues of expert consensus on immunomodulatory therapies for chronic obstructive pulmonary disease
  3. Perspective
  4. Emerging noninvasive neuromodulation methods for functional gastrointestinal diseases
  5. Gastric electrical stimulation: Overview and summary
  6. Antibiotic stewardship: Dead bugs do not mutate
  7. The long and the short of current nanomedicines for treating Alzheimer's disease
  8. Monkeypox: Clinical issues of concern
  9. Cortical synaptic mechanism for chronic pain and anxiety in Parkinson’s disease
  10. Commentary
  11. Chemical therapy for chronic pancreatitis: An assumption or an alternative?
  12. Review Article
  13. Focal liver lesions other than hepatocellular carcinoma in cirrhosis: Diagnostic challenges
  14. The emergence of travel-related infections in critical care units
  15. Research progress on N6-adenosylate methylation RNA modification in heart failure remodeling
  16. Original Article
  17. Characteristics of the severe acute respiratory syndrome coronavirus 2 omicron BA.2 subvariant in Jilin, China from March to May 2022
  18. A comprehensive weighted gene co-expression network analysis uncovers potential targets in diabetic kidney disease
  19. Letter to Editor
  20. Acute kidney injury associated with severe hypouricemia caused by a novel SLC2A9 mutation: Enlightenment from rare disease to common disease
  21. Noted tension headache, anxiety, and depression in a Chinese patient with spinocerebellar ataxia, autosomal recessive 10 caused by a novel anoctamin 10 mutation
https://doi.org/10.2478/jtim-2022-0025
Keywords for this article
RNA modification; m6A RNA methylation; cardiac remodeling; cardiac hypertrophy; heart failure
Creative Commons
BY-NC-ND 3.0

Articles in the same Issue

  1. Editorial
  2. Interpretation of the key issues of expert consensus on immunomodulatory therapies for chronic obstructive pulmonary disease
  3. Perspective
  4. Emerging noninvasive neuromodulation methods for functional gastrointestinal diseases
  5. Gastric electrical stimulation: Overview and summary
  6. Antibiotic stewardship: Dead bugs do not mutate
  7. The long and the short of current nanomedicines for treating Alzheimer's disease
  8. Monkeypox: Clinical issues of concern
  9. Cortical synaptic mechanism for chronic pain and anxiety in Parkinson’s disease
  10. Commentary
  11. Chemical therapy for chronic pancreatitis: An assumption or an alternative?
  12. Review Article
  13. Focal liver lesions other than hepatocellular carcinoma in cirrhosis: Diagnostic challenges
  14. The emergence of travel-related infections in critical care units
  15. Research progress on N6-adenosylate methylation RNA modification in heart failure remodeling
  16. Original Article
  17. Characteristics of the severe acute respiratory syndrome coronavirus 2 omicron BA.2 subvariant in Jilin, China from March to May 2022
  18. A comprehensive weighted gene co-expression network analysis uncovers potential targets in diabetic kidney disease
  19. Letter to Editor
  20. Acute kidney injury associated with severe hypouricemia caused by a novel SLC2A9 mutation: Enlightenment from rare disease to common disease
  21. Noted tension headache, anxiety, and depression in a Chinese patient with spinocerebellar ataxia, autosomal recessive 10 caused by a novel anoctamin 10 mutation
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 19.9.2025 from https://www.degruyterbrill.com/document/doi/10.2478/jtim-2022-0025/html
Scroll to top button